Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
  • About Us
    • Editorial Profile
    • Editorial Calendar
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
 
 
 
 
  • A Mature Capital Structure Positions Bio-IT Startups For Success

    Bio-IT World Contributed Commentary | By establishing a mature capital structure reflecting a healthy balance of both equity and debt, early-stage bio-IT companies can project long-term strength and vision that helps to favorably position them with their stakeholders.

    Dec 6, 2018
  • GSK Bags Tesaro For $5B As It Leaps Back Into Commercial Oncology, Beefs Up Cancer Drug Pipeline

    Endpoints News | GlaxoSmithKline has struck a deal to buy Tesaro in a $5.1 billion deal that will vault the pharma giant into the commercial oncology market as it stakes out a big new role for itself in the booming cancer field.

    Dec 5, 2018
  • OmniTier Debuts CompStor Novos Platform For De Novo Assembly-Based Variant Calling

    Bio-IT World News Brief | OmniTier has debuted the CompStor Novos platform for de novo assembly-based variant calling in whole genome sequencing applications.

    Dec 5, 2018
  • Despite CRISPR Baby Controversy, Harvard University Will Begin Gene-Editing Sperm

    MIT Technology Review | Even as a furious debate broke out in China over gene-edited babies, some scientists in the US are also hoping to improve tomorrow's children.

    Nov 30, 2018
  • «
  • 291
  • 292
  • 293
  • 294
  • 295 (current)
  • 296
  • 297
  • 298
  • 299
  • 300
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: [email protected]

Twitter Icon LinkedIn Icon Facebook Icon

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy